Oncodesign Precision Medicine Société anonyme announced that it has received an equity round of funding for gross proceeds of ?22 million on January 23, 2024. The transaction included participation from new investor NOV Santé Actions Non Cotées, a fund managed by Eurazeo SE; management and ERES IV SLP.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 EUR | +0.71% | -1.74% | -22.10% |
25/01 | Oncodesign Precision Medicine: fundraising on the horizon | CF |
25/01 | Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
85.6 EUR | +0.71% | +0.12% | 6.79B | ||
1.41 EUR | +0.71% | -1.74% | 25.33M | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.10% | 25.33M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ALOPM Stock
- News Oncodesign Precision Medicine
- Oncodesign Precision Medicine Société anonyme announced that it has received ?22 million in funding from Eurazeo SE and other investors